GREAT POST! Let me add a few lines...
Why the need to renew patents?
Why CV Therapeutics has appointed Colin Hislop as Chief Medical Officer?
I'm long and I am very optimistic about the buyout. I believe in NSPX IP portfolio and the patents on both the drug platforms are real that I hope will one day transform this stock.
A few years back Dr Dionne (genspera ceo) stated the pro drug Mipsagargin was 100-Fold stronger than conventional chemotherapeutic. Unlike standard chemotherapy drugs, we see no effect on liver, hair loss, heart, or the bone marrow. This is very interesting it encouraging me to learn, buy and go long on this investment.
In sept 2018 NSPX and Ridgeway entered in to a licensing agreement For IP related to Adenosine drug platforms. As I discover the person who runs Ridgeway Therapeutics (partnering with NSPX to advance and fund our clinical studies) was Colin Hislop, M.D.
“Dr. Hislop is an experienced drug development clinician with over 27 years of experience in both pharmaceutical and biotechnology companies. Over the course of his career, Dr. Hislop has helped secure over $300 million in private and public equity financing.
The shocking truth! CV Therapeutics has appointed Colin Hislop as Chief Medical Officer.
“Dr. Hislop has been involved in numerous regulatory interactions for drugs spanning from pre-IND to advisory committee meetings for approval. Among those drugs with approvals are ActonelTM, which went on to realize $1.0 billion in global sales, and RanexaTM, which Dr. Hislop was one of the key drivers behind Gilead’s purchase of CV Therapeutics for $1.4 billion in 2009.
We can’t refused admitting the ultimate truth of our existence anticancer drug Mipsagargin proven to be a viable tumor killer. Furthermore, we can’t ignore the fact that now Dr. Hislop is the key driver behind Inspyr. The important thing here is the market potential. We don’t know if Dr. Hislop will lead us to a buyout like he did with CV Therapeutics. However, one thing is for sure we are well aware of the bid war yields rich price for biotech.
Bottom line: Let’s keep an open mind to other possibilities that about to happen with this ticker.
Ya have a happy day.
News 
Market Data 
Discover 
